Amending the description of a patent application

Patent applications are legal documents with several sections to them. The most important section is the claims, which define how much legal protection the applicant is seeking for an invention.

CIPA Informals post-exam social

About David Jasiewicz: I’m David, a trainee patent attorney in our Manchester office. I have a background in chemistry and before joining Appleyard Lees I worked in a patent law firm in Japan. Outside of work I enjoy playing tennis, and more recently looking after my new born daughter. In October, trainee patent attorneys sat down […]

Journey to the Leeds 10k

About David Jasiewicz: I’m David, a trainee patent attorney in our Manchester office. I have a background in chemistry and before joining Appleyard Lees I worked in a patent law firm in Japan. Outside of work I enjoy playing tennis, and more recently looking after my new born daughter. Before I joined Appleyard Lees, I didn’t […]

Thoughts on passing the European Qualifying Examinations (EQEs)

About David Jasiewicz: I’m David, a trainee patent attorney in our Manchester office. I have a background in chemistry and before joining Appleyard Lees I worked in a patent law firm in Japan. Outside of work I enjoy playing tennis, and more recently looking after my new born daughter. On the 21st June 2021, I received […]

Tek Talks – our monthly roundtable discussions

Here in the Manchester office, on the second Thursday of every month, all of the technical staff are invited to take part in informal meetings that currently go under the name of TekTalks. 

Patent Box: tax relief for patent owners and patent licensees

As provided in the recent UK budget announcement, the UK corporation tax rate is set to rise from 19 to 25 percent from 1 April 2023. As a result, companies should now be thinking about whether they can make use of the tax relief provided by the Patent Box scheme.

SPC you later to drug-device combinations

On 25 October 2018 the Court of Justice of the European Union (CJEU) handed down its judgment on the case C-527/17 relating to supplementary protection certificates (SPCs) for drug-device combination products. In brief, the CJEU decided that the drug-device combination product in question was not eligible for an SPC. This article considers the background and […]